India’s apex drug regulator on Tuesday approved the phase 2 and 3 clinical trials of Covid vaccine candidate by Pune-based Gennova, which has shown very encouraging results in the early-stage trials.

Importantly, this mRNA-based vaccine will likely be compared with Covishiled, and not placebo while the trials will include about 4,400 participants at 22-24 sites across the country. Also, it may be the first vaccine to be introduced in India specifically designed against the delta variant of SARS CoV 2–the most dominant strain of the virus in India and elsewhere.

Leave a Reply

Your email address will not be published. Required fields are marked *

India’s apex drug regulator on Tuesday approved the phase 2 and 3 clinical trials of Covid vaccine candidate by Pune-based Gennova, which has shown very encouraging results in the early-stage trials.

Importantly, this mRNA-based vaccine will likely be compared with Covishiled, and not placebo while the trials will include about 4,400 participants at 22-24 sites across the country. Also, it may be the first vaccine to be introduced in India specifically designed against the delta variant of SARS CoV 2–the most dominant strain of the virus in India and elsewhere.

Leave a Reply

Your email address will not be published. Required fields are marked *